Connect with us

Hi, what are you looking for?

Alive Business PlanAlive Business Plan

Stock

UBS upgrades Azelis to ‘buy,’ citing recovery and attractive valuation

Investing.com — UBS Global Research has upgraded Azelis Group (EBR:AZE) to a “buy” rating from its previous “neutral” stance.

Shares of the Belgium-based company were up 3.8% at 08:12 ET (13:12 GMT).

UBS believes profit pressures have peaked, making the company’s current valuation attractive.

Azelis saw profit normalization in 2024, following a period of exceptional growth from 2020 to 2022

While the chemical distribution sector faced challenges in the past year, UBS projects 2025 to be a more typical year, characterized by modest volume recovery and easing pricing pressures.

The analysts foresee conversion margins stabilizing at about 45%, which remains higher than pre-2020 levels and above the low 40% range implied by current market valuations.

UBS has adjusted its price target for Azelis upward, from €19 to €22, reflecting a 1% increase in expected earnings per share and the inclusion of potential bolt-on mergers and acquisitions into its discounted cash flow valuation model.

The brokerage notes that Azelis has historically been active in mergers and acquisitions, a key growth strategy in the fragmented chemical distribution market.

With a conservative assumption of €150 million in annual mergers and acquisitions spending, the valuation captures the company’s ongoing potential to expand its market share.

Despite cautious commentary from Azelis management regarding customer ordering patterns, UBS forecasts a 4.5% year-over-year volume growth for 2025.

Pricing pressures may persist into the first half of the year, but the overall risk of a margin reset appears limited.

The analysts also flag the resilience of the chemical distribution industry, which benefits from structural growth and defensive demand patterns.

Trading at around 12 times its estimated 2025 EV/EBITA, Azelis represents a 25% discount compared to peer IMCD (AS:IMCD), despite comparable growth outlooks.

UBS flags an attractive entry point for investors due to Azelis’s valuation gap. Analysts said that the company’s long-term growth potential as a top-three player in a diverse and expanding market.

This post appeared first on investing.com
Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    You May Also Like

    Latest News

    The Gateway Pundit, a far-right website, published a note from its editor on Saturday acknowledging that two election workers in Georgia did not engage...

    Latest News

    Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

    Investing

    JAKARTA (Reuters) -Indonesia has asked Alphabet (NASDAQ:GOOGL)’s Google and Apple (NASDAQ:AAPL) to block Chinese fast fashion e-commerce firm Temu in their application stores in...

    Latest News

    New majorities in Congress, particularly when the incoming party has a new leader, offer the rare chance for the institution to take a breath...



    Disclaimer: alivebusinessplan.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 alivebusinessplan.com